Yaya Capital

ISA is a digital-first home healthcare provider harnessing technology to bring care directly to patients' home, providing higher quality services at a fraction of the cost. Currently, ISA offers outpatient care, lab work services and immunizations. We are aiming to be the largest non-hospital healthcare company in Latam, by providing access to affordable healthcare services for millions of people through the decentralization of care.

Endpoint Health is a precision immunology company that is breaking the efficacy barrier of traditional pharma's “one-size-fits-all” drug development strategy by developing precision therapies with outsized efficacy potential in autoimmune and inflammatory conditions. They’re accomplishing this by leveraging OMNAI, their proprietary AI-powered patient discovery platform, to identify and match high-potential therapies to the patients most likely to respond.

Klivo is a health technology company that operates a patient management platform designed to support individuals with chronic conditions in leading healthier lives. The platform enables real-time monitoring of health conditions and facilitates the transmission of blood glucose data. Additionally, it provides users with answers to questions related to clinical conditions, nutrition, and other relevant topics. By equipping healthcare professionals with essential data and insights, Klivo aims to enhance clinical outcomes for patients managing chronic illnesses.

Endpoint Health is a precision immunology company that is breaking the efficacy barrier of traditional pharma's “one-size-fits-all” drug development strategy by developing precision therapies with outsized efficacy potential in autoimmune and inflammatory conditions. They’re accomplishing this by leveraging OMNAI, their proprietary AI-powered patient discovery platform, to identify and match high-potential therapies to the patients most likely to respond.

Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.